**Table A.1. Timing of Tdap vaccination among pregnant women aged 15-49 years, Marketscan 2009-2016 (37 weeks)\***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Year**  | **Received before pregnancy(%)** | **Received** **during pregnancy (%)** | **Received postpartum\* (%)** | **Received at any point during pregnancy\*\*** |
| **Received during 1st trimester\*\* (%)** | **Received during 2nd trimester\*\*** **(%)** | **Received during 3rd trimester\*\*** **(%)** |
| **27 weeks-****32 weeks 6 days** | **33 weeks-****36 weeks 6 days** | **37 weeks** |
| 2009 | 1.4 | 0.3 | 0.6 |  50.3  |  18.7  |  6.0  |  7.0  |  17.9  |
| 2010 | 1.6 | 0.8 | 1.4 |  24.5  |  18.5  |  24.4  |  22.5  |  10.1  |
| 2011 | 2.0 | 1.9 | 1.7 |  22.6  |  25.6  |  25.1  |  19.9  |  6.8  |
| 2012 | 2.0 | 6.0 | 1.5 |  6.2  |  30.8  |  36.2  |  24.3  |  2.5  |
| 2013 | 1.7 | 21.7 | 1.2 |  2.0  |  31.5  |  46.5  |  19.2  |  0.8  |
| 2014 | 1.1 | 37.7 | 0.8 |  0.7  |  30.7  |  52.9  |  15.3  |  0.4  |
| 2015 | 0.8 | 48.3 | 0.6 |  0.5  |  31.4  |  54.8  |  13.0  |  0.3  |
| 2016 | 0.6  | 53.1  | 0.6 |  0.3  |  31.4  |  56.0  |  11.9  |  0.3  |

\* The estimates in this table were derived via a sensitivity analysis that assumed every woman in the study cohort delivered at 37 weeks gestation. Therefore, postpartum vaccination estimates represent all Tdap vaccine doses received after 37 weeks gestation.

\*\* Data in these columns represent the proportion of women vaccinated at any point during pregnancy who received Tdap vaccine during the time period specified. First trimester: 0 weeks through 13 weeks 6 days gestation; second trimester: 14 weeks through 26 weeks 6 days gestation; third trimester: 27 weeks through 37 weeks gestation.

**Table A.2. Timing of Tdap vaccination among pregnant women aged 15-49 years, Marketscan 2009-2016 (38 weeks)\***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Year**  | **Received before pregnancy(%)** | **Received** **during pregnancy (%)** | **Received postpartum\* (%)** | **Received at any point during pregnancy\*\*** |
| **Received during 1st trimester\*\* (%)** | **Received during 2nd trimester\*\*** **(%)** | **Received during 3rd trimester\*\*** **(%)** |
| **27 weeks-****32 weeks 6 days** | **33 weeks-****36 weeks 6 days** | **37 weeks-****38 weeks** |
| 2009 | 1.4 | 0.3 | 0.6 | 55.9 | 17.2 | 5.0 | 4.7 | 17.3 |
| 2010 | 1.6 | 0.8 | 1.4 | 27.9 | 14.4 | 23.1 | 19.6 | 14.9 |
| 2011 | 2.0 | 2.0 | 1.7 | 23.5 | 24.2 | 22.6 | 18.4 | 11.2 |
| 2012 | 2.0 | 6.1 | 1.5 | 6.8 | 24.7 | 35.1 | 26.4 | 6.9 |
| 2013 | 1.7 | 21.8 | 1.2 | 2.1 | 22.3 | 49.0 | 22.9 | 3.6 |
| 2014 | 1.1 | 37.8 | 0.8 | 0.7 | 19.0 | 58.1 | 19.8 | 2.3 |
| 2015 | 0.8 | 48.4 | 0.6 | 0.5 | 19.0 | 61.3 | 17.5 | 1.7 |
| 2016 | 0.6 | 53.1  | 0.6 | 0.3 | 18.1 | 63.7 | 16.3 | 1.5 |

\* The estimates in this table were derived via a sensitivity analysis that assumed every woman in the study cohort delivered at 38 weeks gestation. Therefore, postpartum vaccination estimates represent all Tdap vaccine doses received after 38 weeks gestation.

\*\*Data in these columns represent the proportion of women vaccinated at any point during pregnancy who received Tdap vaccine during the time period specified. First trimester: 0 weeks through 13 weeks 6 days gestation; second trimester: 14 weeks through 26 weeks 6 days gestation; third trimester: 27 weeks through 38 weeks gestation.

**Table A.3. Timing of Tdap vaccination among pregnant women aged 15-49 years, Marketscan 2009-2016 (39 weeks)\***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Year**  | **Received before pregnancy(%)** | **Received** **during pregnancy (%)** | **Received postpartum\* (%)** | **Received at any point during pregnancy\*\*** |
| **Received during 1st trimester\*\* (%)** | **Received during 2nd trimester\*\*** **(%)** | **Received during 3rd trimester\*\*** **(%)** |
| **27 weeks-****32 weeks 6 days** | **33 weeks-****36 weeks 6 days** | **37 weeks-****39 weeks** |
| 2009 | 1.4 | 0.4 | 0.6 | 57.7 | 16.1 | 5.0 | 5.0 | 16.2 |
| 2010 | 1.6 | 0.9 | 1.4 | 31.6 | 12.3 | 19.2 | 18.3 | 18.7 |
| 2011 | 2.0 | 2.1 | 1.7 | 24.8 | 22.1 | 20.4 | 17.7 | 15.0 |
| 2012 | 2.0 | 6.2 | 1.5 | 7.8 | 19.1 | 34.7 | 25.5 | 12.8 |
| 2013 | 1.7 | 21.9 | 1.2 | 2.3 | 14.6 | 50.0 | 25.5 | 7.6 |
| 2014 | 1.1 | 37.8 | 0.8 | 0.8 | 9.6 | 60.3 | 24.0 | 5.3 |
| 2015 | 0.8 | 48.4 | 0.6 | 0.5 | 8.9 | 64.6 | 21.8 | 4.2 |
| 2016 | 0.6  | 53.1  | 0.6 | 0.4 | 8.0 | 66.9 | 20.9 | 3.7 |

\* The estimates in this table were derived via a sensitivity analysis that assumed every woman in the study cohort delivered at 39 weeks gestation. Therefore, postpartum vaccination estimates represent all Tdap vaccine doses received after 39 weeks gestation.

\*\*Data in these columns represent the proportion of women vaccinated at any point during pregnancy who received Tdap vaccine during the time period specified. First trimester: 0 weeks through 13 weeks 6 days gestation; second trimester: 14 weeks through 26 weeks 6 days gestation; third trimester: 27 weeks through 39 weeks gestation.

**Table A.4. Timing of Tdap vaccination among pregnant women aged 15-49 years, Marketscan 2009-2016 (41 weeks)\***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Year**  | **Received before pregnancy(%)** | **Received** **during pregnancy (%)** | **Received postpartum\* (%)** | **Received at any point during pregnancy\*\*** |
| **Received during 1st trimester\*\* (%)** | **Received during 2nd trimester\*\*** **(%)** | **Received during 3rd trimester\*\*** **(%)** |
| **27 weeks-****32 weeks 6 days** | **33 weeks-****36 weeks 6 days** | **37 weeks-****41 weeks** |
| 2009 | 1.3 | 0.5 | 0.6 | 65.2% | 13.2% | 3.9% | 3.3% | 14.4% |
| 2010 | 1.5 | 1.0 | 1.4 | 38.1% | 9.7% | 11.5% | 14.9% | 25.8% |
| 2011 | 1.9 | 2.2 | 1.7 | 27.1% | 20.2% | 14.2% | 15.4% | 23.1% |
| 2012 | 2.0 | 6.3 | 1.5 | 9.1% | 12.9% | 29.0% | 23.4% | 25.6% |
| 2013 | 1.6 | 22.0 | 1.2 | 2.5% | 7.4% | 41.4% | 28.9% | 19.7% |
| 2014 | 1.1 | 37.9 | 0.8 | 0.9% | 2.4% | 49.5% | 31.5% | 15.7% |
| 2015 | 0.7 | 48.5 | 0.6 | 0.5% | 1.6% | 53.1% | 31.5% | 13.3% |
| 2016 | 0.6  | 53.2  | 0.6 | 0.4% | 1.1% | 54.7% | 31.5% | 12.2% |

\* The estimates in this table were derived via a sensitivity analysis that assumed every woman in the study cohort delivered at 41 weeks gestation. Therefore, postpartum vaccination estimates represent all Tdap vaccine doses received after 41 weeks gestation.

\*\*Data in these columns represent the proportion of women vaccinated at any point during pregnancy who received Tdap vaccine during the time period specified. First trimester: 0 weeks through 13 weeks 6 days gestation; second trimester: 14 weeks through 26 weeks 6 days gestation; third trimester: 27 weeks through 41 weeks gestation.